Antoine Thyss
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antoine Thyss has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Yves Blay
Medical Oncology Department Centre Léon Bérard Lyon France
4 shared publications - Antoine Italiano
Institut Bergonié, Bordeaux, France
3 shared publications - Nicolas Penel
Department of Medical Oncology Centre Oscar Lambret Lille France
3 shared publications - Sophie Piperno-Neumann
Medical Oncology Department Institut Curie Paris France
3 shared publications - Christine Chevreau
Department of Medical Oncology, Oncopole, Toulouse, France
2 shared publications - Emmanuelle Bompas
Department of Medical Oncology, Institute de Cancérologie de l’Ouest, Saint-Herblain, France
2 shared publications
Latest Publications
- 19 June 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (9) , 110202
Radiation-associated angiosarcoma of the breast: consider chemotherapy
- 19 June 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (9) , 110202
Radiation-associated angiosarcoma of the breast: consider chemotherapy
- Open Access
- 30 November 2018
- Published by Springer Nature in Journal of Therapeutic Ultrasound
- Vol. 6 (1) , 8
Focused ultrasound for the treatment of bone metastases: effectiveness and feasibility
To evaluate the effectiveness and feasibility of high-intensity focused ultrasound (HIFU) for the treatment of bone metastases. A single-center prospective study was made involving 17 consecutive patients with symptomatic bone metastases. Patients were treated by Focused Ultrasound (FUs) performed with magnetic resonance (MR) guidance. Surgical treatment or radiotherapy treatment was not indicated for patients who underwent FUs. Lesions were located in the appendicular and axial skeleton and consisted of secondary symptomatic lesions. The clinical course of pain was evaluated using the Visual Analog Scale (VAS) before treatment, at 1 week, and at 1 month after treatment and the Oral Morphine Equivalent Daily Dose (OMEDD) was also recorded. We used Wilcoxon signed rank test to assess change in patient pain (R CRAN software V 3.1.1). We observed a significant decrease in the pain felt by patients between pre- procedure and 1 week post-procedure (p = 2.9.10–4), and pre-procedure and 1 month post-procedure (p = 3.10–4). The proportion of responders according to the International Bone Metastases Consensus Working Party was: Partial Response 50% (8/16) and Complete Response 37.5% (6/16). HIFU under MR-guidance seems to be an effective and safe procedure in the treatment of symptomatic bone lesions for patients suffering from metastatic disease. A significant decrease of patient pain was observed. NCT01091883 . Registered 24 March 2010. Level of evidence: Level 3.
- 30 November 2018
- Published by Springer Nature in Journal of Therapeutic Ultrasound
- Vol. 6 (1) , 8
Open AccessFocused ultrasound for the treatment of bone metastases: effectiveness and feasibility
To evaluate the effectiveness and feasibility of high-intensity focused ultrasound (HIFU) for the treatment of bone metastases. A single-center prospective study was made involving 17 consecutive patients with symptomatic bone metastases. Patients were treated by Focused Ultrasound (FUs) performed with magnetic resonance (MR) guidance. Surgical treatment or radiotherapy treatment was not indicated for patients who underwent FUs. Lesions were located in the appendicular and axial skeleton and consisted of secondary symptomatic lesions. The clinical course of pain was evaluated using the Visual Analog Scale (VAS) before treatment, at 1 week, and at 1 month after treatment and the Oral Morphine Equivalent Daily Dose (OMEDD) was also recorded. We used Wilcoxon signed rank test to assess change in patient pain (R CRAN software V 3.1.1). We observed a significant decrease in the pain felt by patients between pre- procedure and 1 week post-procedure (p = 2.9.10–4), and pre-procedure and 1 month post-procedure (p = 3.10–4). The proportion of responders according to the International Bone Metastases Consensus Working Party was: Partial Response 50% (8/16) and Complete Response 37.5% (6/16). HIFU under MR-guidance seems to be an effective and safe procedure in the treatment of symptomatic bone lesions for patients suffering from metastatic disease. A significant decrease of patient pain was observed. NCT01091883 . Registered 24 March 2010. Level of evidence: Level 3.
- 21 July 2016
- Published by Elsevier in Bulletin du Cancer
- Vol. 103 (9) , 735-742
Évaluation de l’utilisation de la TEP au FDG pour le bilan des sarcomes de l’adulte en pratique quotidienne
- 21 July 2016
- Published by Elsevier in Bulletin du Cancer
- Vol. 103 (9) , 735-742
Évaluation de l’utilisation de la TEP au FDG pour le bilan des sarcomes de l’adulte en pratique quotidienne
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 11013
Improved sarcoma management in a national network of reference centers: Analysis of the NetSarc network on 13,454 patients treated between 2010 and 2014.
11013 Background: Since 2009 a network of 26 reference multidisciplinary centers aiming to improve the quality of care for sarcoma patients (pts) in France was granted by the French National Cancer Institute. We report here on the results of this network on patient management after 5 years. Methods: Data of the NetSarc network database include pts characteristics, previous treatment and diagnosis procedures, medical decision, survival and progression. From Jan 2010 to Dec 2014, 13454 newly diagnosed pts were included, soft tissue and visceral representing 10427 (77%) and 3027 (23%) respectively. These represent an estimated 78% of sarcoma case in France in 5 years. Individual Netsarc enters managed a median of 325 (range 39-1529) pts in 5 years. Results: 6955 women (52%) and 6499 men (48%), with a median age of 60y (range 0-101) were included. Soft tissue and visceral represented 10427 (77%) and 3027 (23%) pts respectively. LMS (12%), GIST (8.2%), DDLPS (7.3%) and UPS (11%) were the most frequent histotypes. 12% pts had metastases at diagnosis. Between 2010 and 2015, the proportion of pts reviewed in Netsarc reference centers prior to surgery increased from 41% to 48%. A higher number of pts managed in Netsarc centers had proper imaging of the primary tumor prior to surgery (86% vs 59%, p<0.0001), and had biopsy prior the first resection (80% vs 36%, p<0.0001). 10265 (76%) pts had a surgery, 4304 (42%) within the Netsarc network and 4639 (45%) outside the network, and unknown in 1322 (13%) pts). Patients whose primary surgery was performed in Netsarc centers had R0, R1, R2, and R (unknown or non evaluable) surgery in 49%, 27%, 7%, 16% vs 24%, 31%, 21%, 23% in centers outside Netsarc (p<0.000001). 865 (19%) pts had secondary resection after primary surgery in non NetSarc centers vs 252 (6%) in NetSARC centers (p<0.0001). Progression free survival (PFS) was better in patients managed in Netsarc reference centers (p=0.0008). Conclusions: Sarcoma pts managed in reference centers have a significantly higher rate of management according to CPGs, R0 surgery, less reoperations, and better PFS. The number of patients managed prior to surgery in reference centers increases slightly overtime.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 11013
Improved sarcoma management in a national network of reference centers: Analysis of the NetSarc network on 13,454 patients treated between 2010 and 2014.
11013 Background: Since 2009 a network of 26 reference multidisciplinary centers aiming to improve the quality of care for sarcoma patients (pts) in France was granted by the French National Cancer Institute. We report here on the results of this network on patient management after 5 years. Methods: Data of the NetSarc network database include pts characteristics, previous treatment and diagnosis procedures, medical decision, survival and progression. From Jan 2010 to Dec 2014, 13454 newly diagnosed pts were included, soft tissue and visceral representing 10427 (77%) and 3027 (23%) respectively. These represent an estimated 78% of sarcoma case in France in 5 years. Individual Netsarc enters managed a median of 325 (range 39-1529) pts in 5 years. Results: 6955 women (52%) and 6499 men (48%), with a median age of 60y (range 0-101) were included. Soft tissue and visceral represented 10427 (77%) and 3027 (23%) pts respectively. LMS (12%), GIST (8.2%), DDLPS (7.3%) and UPS (11%) were the most frequent histotypes. 12% pts had metastases at diagnosis. Between 2010 and 2015, the proportion of pts reviewed in Netsarc reference centers prior to surgery increased from 41% to 48%. A higher number of pts managed in Netsarc centers had proper imaging of the primary tumor prior to surgery (86% vs 59%, p<0.0001), and had biopsy prior the first resection (80% vs 36%, p<0.0001). 10265 (76%) pts had a surgery, 4304 (42%) within the Netsarc network and 4639 (45%) outside the network, and unknown in 1322 (13%) pts). Patients whose primary surgery was performed in Netsarc centers had R0, R1, R2, and R (unknown or non evaluable) surgery in 49%, 27%, 7%, 16% vs 24%, 31%, 21%, 23% in centers outside Netsarc (p<0.000001). 865 (19%) pts had secondary resection after primary surgery in non NetSarc centers vs 252 (6%) in NetSARC centers (p<0.0001). Progression free survival (PFS) was better in patients managed in Netsarc reference centers (p=0.0008). Conclusions: Sarcoma pts managed in reference centers have a significantly higher rate of management according to CPGs, R0 surgery, less reoperations, and better PFS. The number of patients managed prior to surgery in reference centers increases slightly overtime.
- Open Access
- 5 November 2015
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 1-9
Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC’S (Observatoire de l’Utilisation des Thérapies Ciblées dans les Sarcomes)
The objective of this study is to explore the off-label use of targeted therapies (TTs) for patients with osteosarcoma registered within the French Sarcoma Group – Bone Tumor Study Group (GSF-GETO) national registry. All patients with an osteosarcoma, registered between January 1, 2009 and July 15, 2013 were analyzed. Twenty-nine patients with refractory relapsed osteosarcomas received 33 treatment lines of TTs. The median age at the beginning of treatment was 19 years (range 9–72). The median number of previous lines of chemotherapy was 3 (range 1–8). Before inclusion, 3 patients were in second complete remission, 26 were in progression for metastatic relapse. Twenty-three patients received sirolimus (in combination with cyclophosphamide for 18); 5, sunitinib; 4, sorafenib; and one, pazopanib. Stable disease was observed for 45.5 % of patients (95 % Confidence Interval (CI) [20–52.8]). The median Progression-Free Survival (PFS) was 3 months (95 % CI [2–5.4]) for patients treated by sirolimus and 1.8 months (95 % CI [1.3–2.8]) for patients receiving multi-targeted tyrosine kinase inhibitors; 6-month PFS 15 %. The median Overall Survival (OS) was 6.8 months (95 % CI [4.7–12.1]), and one-year OS was 24 %. In a multivariate analysis, PFS was superior for patients receiving sirolimus compared to other TTs (Hazard Ratio (HR) = 2.7, 95 % CI [1.05–7.1]). No toxic death was reported. Grade 3 and 4 toxicities were observed in 27 and 6 % of cases respectively. Off-label TTs, especially sirolimus, reported benefit in the treatment of refractory osteosarcomas with an acceptable toxicity profile, including in pediatric population.
- 5 November 2015
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 1-9
Open AccessOff-label use of targeted therapies in osteosarcomas: data from the French registry OUTC’S (Observatoire de l’Utilisation des Thérapies Ciblées dans les Sarcomes)
The objective of this study is to explore the off-label use of targeted therapies (TTs) for patients with osteosarcoma registered within the French Sarcoma Group – Bone Tumor Study Group (GSF-GETO) national registry. All patients with an osteosarcoma, registered between January 1, 2009 and July 15, 2013 were analyzed. Twenty-nine patients with refractory relapsed osteosarcomas received 33 treatment lines of TTs. The median age at the beginning of treatment was 19 years (range 9–72). The median number of previous lines of chemotherapy was 3 (range 1–8). Before inclusion, 3 patients were in second complete remission, 26 were in progression for metastatic relapse. Twenty-three patients received sirolimus (in combination with cyclophosphamide for 18); 5, sunitinib; 4, sorafenib; and one, pazopanib. Stable disease was observed for 45.5 % of patients (95 % Confidence Interval (CI) [20–52.8]). The median Progression-Free Survival (PFS) was 3 months (95 % CI [2–5.4]) for patients treated by sirolimus and 1.8 months (95 % CI [1.3–2.8]) for patients receiving multi-targeted tyrosine kinase inhibitors; 6-month PFS 15 %. The median Overall Survival (OS) was 6.8 months (95 % CI [4.7–12.1]), and one-year OS was 24 %. In a multivariate analysis, PFS was superior for patients receiving sirolimus compared to other TTs (Hazard Ratio (HR) = 2.7, 95 % CI [1.05–7.1]). No toxic death was reported. Grade 3 and 4 toxicities were observed in 27 and 6 % of cases respectively. Off-label TTs, especially sirolimus, reported benefit in the treatment of refractory osteosarcomas with an acceptable toxicity profile, including in pediatric population.
- Open Access
- 4 July 2015
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 4 (1) , 18
Z-BeEAM (Ibritumomab tiuxetan, Bendamustine, Etoposide, Cytarabine, Melphalan) before autologous stem cell transplantation is safe and efficient for refractory large B-cell lymphoma
Refractory or relapsed large B-cells lymphoma are usually treated with a high dose chemotherapy regimen followed by an autolougous stem cells transplantation. BEAM (carmustine, etoposide, cytarabine, melphalan) or more recently Z-BEAM (ibritumomab tiuxetan and BEAM) are commonly used regimens, but recently carmustine availability became difficult. The purpose of this study was to evaluate the feasibility and the safety of replacing carmustine by bendamustine in a new Z-BeEAM regimen (ibritumomab tiuxetan, bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplantation. This study was a retrospective analyze of six patients, with a median age of 60, treated by Z-BeEAM before autologous stem cell transplantation. We did not put in evidence any additional toxicities compared to conventional induction chemotherapy. The main toxicities were mucositis (3 grade III among 6 patients), gastrointestinal (2 grade III vomiting and 2 grade III diarrhea) and neutropenia (6 grade IV). Engraftment was successfully achieved for all patients. At the time of analysis of this study all patients were alive and in complete response based on the PET-CT evaluation. BeEAM plus ibritumomab tiuxetan combined regimen before autologous stem cell transplantation is feasible and safe in aggressive relapsing large B-cell lymphoma.
- 4 July 2015
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 4 (1) , 18
Open AccessZ-BeEAM (Ibritumomab tiuxetan, Bendamustine, Etoposide, Cytarabine, Melphalan) before autologous stem cell transplantation is safe and efficient for refractory large B-cell lymphoma
Refractory or relapsed large B-cells lymphoma are usually treated with a high dose chemotherapy regimen followed by an autolougous stem cells transplantation. BEAM (carmustine, etoposide, cytarabine, melphalan) or more recently Z-BEAM (ibritumomab tiuxetan and BEAM) are commonly used regimens, but recently carmustine availability became difficult. The purpose of this study was to evaluate the feasibility and the safety of replacing carmustine by bendamustine in a new Z-BeEAM regimen (ibritumomab tiuxetan, bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplantation. This study was a retrospective analyze of six patients, with a median age of 60, treated by Z-BeEAM before autologous stem cell transplantation. We did not put in evidence any additional toxicities compared to conventional induction chemotherapy. The main toxicities were mucositis (3 grade III among 6 patients), gastrointestinal (2 grade III vomiting and 2 grade III diarrhea) and neutropenia (6 grade IV). Engraftment was successfully achieved for all patients. At the time of analysis of this study all patients were alive and in complete response based on the PET-CT evaluation. BeEAM plus ibritumomab tiuxetan combined regimen before autologous stem cell transplantation is feasible and safe in aggressive relapsing large B-cell lymphoma.
- 11 March 2015
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 29 (2) , 204-208
Are nilotinib‐associated vascular adverse events an under‐estimated problem?
Vascular adverse events have been reported with nilotinib, a tyrosine kinase inhibitor prescribed for chronic myeloid leukaemia. However, few data specify their incidence, or whether they occur in predisposed patients. Hence, we prospectively studied 30 consecutive patients to assess the frequency of such adverse reactions and determine whether the patients presenting with these adverse events bear predisposing factors. From 3 to 73 months after nilotinib initiation, 10 of the 30 patients experienced vascular events. Three patients of these 10 were devoid of any patent cardiovascular risk factor, except for age. This study points out an occurrence more frequent than expected of vascular adverse events associated with nilotinib (> 30% vs. < 1% in summary of product characteristics), and particularly of vascular events of late onset in patients with no pre-existing risk factors.
- 11 March 2015
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 29 (2) , 204-208
Are nilotinib‐associated vascular adverse events an under‐estimated problem?
Vascular adverse events have been reported with nilotinib, a tyrosine kinase inhibitor prescribed for chronic myeloid leukaemia. However, few data specify their incidence, or whether they occur in predisposed patients. Hence, we prospectively studied 30 consecutive patients to assess the frequency of such adverse reactions and determine whether the patients presenting with these adverse events bear predisposing factors. From 3 to 73 months after nilotinib initiation, 10 of the 30 patients experienced vascular events. Three patients of these 10 were devoid of any patent cardiovascular risk factor, except for age. This study points out an occurrence more frequent than expected of vascular adverse events associated with nilotinib (> 30% vs. < 1% in summary of product characteristics), and particularly of vascular events of late onset in patients with no pre-existing risk factors.
- Open Access
- 24 November 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 870
The off-label use of targeted therapies in sarcomas: the OUTC’S program
- 24 November 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 870
Open AccessThe off-label use of targeted therapies in sarcomas: the OUTC’S program
- Open Access
- 2 January 2014
- Published by Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy in Mediterranean Journal of Hematology and Infectious Diseases
- Vol. 6 (1) , e2014050
HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?
Hodgkin Lymphoma HL ica be cured in the large majority of younger patients, but prognosis for older patients, especially those with advanced-stage disease, has not improved substantially. The percentage of HL patients aged over 60 ranges between 15% and 35%.A minority of them is enrolled into clinical trials. HL in the elderly have some specificities: more frequent male sex, B-symptoms, advanced stage, sub diaphragmatic presentation, higher percentage of mixed cellularity, up to 50% of advanced cases associated to EBV. Very old age (>70) and comorbidities are factor of further worsening prognosis. Like in younger patients, ABVD is the most used protocol, but treatment outcome remains much inferior with more frequent, severe and sometimes specific toxicities. Few prospective studies with specific protocols are available. The main data have been published by the Italian Lymphoma Group with the VEPEMB schedule and the German Hodgkin Study Group with the PVAG regimen. Recently, the Scotland and Newcastle Lymphoma Study Group published the SHIELD program associating a prospective phase 2 trial with VEPEMB and a prospective registration of others patients. Patients over 60y with early-stage disease received three cycles plus radiotherapy and had 81% of 3-year overall survival (OS).Those with advanced-stage disease received six cycles, with 3-year OS of 66%.The role of geriatric and comorbidity assessment in the treatment’s choice for HL in the elderly is a major challenge. The combination of loss of activities of daily living combined with the age stratification more or less 70y has been shown as a simple and effective survival model. Hopes come from promising new agents like brentuximab-vedotin (BV) a novel antibody-drug conjugate. The use of TEP to adapt the combination of chemotherapy and radiotherapy according to the metabolic response could also be way for prospective studies.
- 2 January 2014
- Published by Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy in Mediterranean Journal of Hematology and Infectious Diseases
- Vol. 6 (1) , e2014050
Open AccessHODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?
Hodgkin Lymphoma HL ica be cured in the large majority of younger patients, but prognosis for older patients, especially those with advanced-stage disease, has not improved substantially. The percentage of HL patients aged over 60 ranges between 15% and 35%.A minority of them is enrolled into clinical trials. HL in the elderly have some specificities: more frequent male sex, B-symptoms, advanced stage, sub diaphragmatic presentation, higher percentage of mixed cellularity, up to 50% of advanced cases associated to EBV. Very old age (>70) and comorbidities are factor of further worsening prognosis. Like in younger patients, ABVD is the most used protocol, but treatment outcome remains much inferior with more frequent, severe and sometimes specific toxicities. Few prospective studies with specific protocols are available. The main data have been published by the Italian Lymphoma Group with the VEPEMB schedule and the German Hodgkin Study Group with the PVAG regimen. Recently, the Scotland and Newcastle Lymphoma Study Group published the SHIELD program associating a prospective phase 2 trial with VEPEMB and a prospective registration of others patients. Patients over 60y with early-stage disease received three cycles plus radiotherapy and had 81% of 3-year overall survival (OS).Those with advanced-stage disease received six cycles, with 3-year OS of 66%.The role of geriatric and comorbidity assessment in the treatment’s choice for HL in the elderly is a major challenge. The combination of loss of activities of daily living combined with the age stratification more or less 70y has been shown as a simple and effective survival model. Hopes come from promising new agents like brentuximab-vedotin (BV) a novel antibody-drug conjugate. The use of TEP to adapt the combination of chemotherapy and radiotherapy according to the metabolic response could also be way for prospective studies.